Children's Mercy Hospital
Children's Mercy Hospital is one of twenty-five type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Wayne Moore, MD, PhD the TrialNet team at Children's Mercy is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.
Dr. Moore is Co-Principal Investigator for the Clinical Center at Children’s Mercy Hospital in Kansas City. His primary interests in diabetes research have been prevention of diabetes and its complications at a translational and clinical level. He is a Certified Physician Investigator through the Association of Clinical Research Professionals. Dr. Moore has been at Children’s Mercy Hospital for over 20 years and was at University of Kansas Medical Center prior to Children’s Mercy. MD, PhD and Pediatric Residency were completed at University of Minnesota.
Dr. Clements is Co-Principal Investigator for the Clinical Center at Children’s Mercy Hospital in Kansas City. His primary interests in diabetes research have been prevention of diabetes and its complications, and the use of big data predictive analytics to improve diabetes care. He is a Certified Physician Investigator through the Association of Clinical Research Professionals. Dr. Clements has been at Children’s Mercy Hospital for 13 years. He attended Butler University, then trained in the Medical Scientist Training Program (MD/PhD program) at Washington University in St Louis. He completed his Pediatric Residency and Endocrine/Diabetes Fellowship at Children’s Mercy Kansas City.
Dr. Huerta-Saenz is a pediatric endocrinologist at the Children’s Mercy Wichita specialty clinic, and Adjunct Assistant Professor of Pediatrics at the University of Missouri, Kansas City. She also has a joint appointment at the Kansas University -Wichita School of Medicine as a Clinical Assistant Professor. Dr. Huerta-Saenz, has experience monitoring clinical trials and has advanced training in “Good clinical practices”. She worked as a clinical research associate at Quintiles Transnational Inc. for 2.5 years, and performed monitoring of phase 2 &3 multicenter clinical trials before her training as a pediatrician. Dr. Huerta-Saenz also has prior experience performing site selection; site monitoring and site close out visits for clinical trials. She also received further statistic analysis training at Pontificia Universidad Catolica del Peru receiving a diploma in applied statistics.
Ryan McDonough, DO, FAAP is a Pediatric Endocrinologist and the Co-Medical Director of the Children’s Diabetes Center. His expertise is in the use of clinical and medical informatics to improve management of clinical trials and health care delivery, and in the care of children and adolescents with Type 1 Diabetes. His role in the Clinical Center is recruiting and assisting in prevention trials. He completed his medical school at Des Moines University in Des Moines, IA, and Pediatrics Residency and Pediatric Endocrinology & Diabetes Fellowship at Children’s Mercy.
Fadi Al Muhaisen, MD, FAAP is a Pediatric Endocrinologist and the Co-Medical Director of the Endocrine Disorders in Cancer patients clinic. He has a joint appointment at the Kansas University-Wichita School of Medicine as a Clinical Assistant Professor. His expertise is in the use of clinical and research to improve management of clinical trials and health care delivery, and in the care of children and adolescents with Type 1 Diabetes. His role in the Clinical Center is recruiting and assisting in prevention trials. Dr. Al Muhaisen is a member of the American Academy of Pediatrics, board certified, and a member of Pediatric Endocrine Society
Misty Whisenhunt , RN
Lois Hester, RN, CCRC
Jennifer James, BA
Julie de la Garza, RN, BSN, CCRP
Jen Bedard, BA, CCRC
Liz Ramey, MS, RD, LD
Dara Watkins, MA, CCRP
Susan Mitchell, RN, BSN
Casey McClain, BPS, MHA, CCRC
Erica Livingston, RN
Kelsye Howell, RN
Jill Sexton, RN
Barb Seuferling, RN
Steve Orlich, RN, ACRP-CP
If you have a relative with T1D, you may be eligible for risk screening that can detect the early stages of T1D years before symptoms appear. More
Depending on your risk screening results, you may be eligible for monitoring. We’ll monitor you for disease progression and let you know if you become eligible for a study. More
We are testing the drug hydroxychloroquine (HCQ) to see if it can delay or prevent early stage T1D (stage 1) from progressing to abnormal glucose tolerance (stage 2) and ultimately prevent clinical diagnosis (stage 3). HCQ is already used to reduce symptoms and progression of other autoimmune diseases, such as rheumatoid arthritis and lupus. This is the first study to see if it can prevent or delay T1D. Details
TrialNet is testing the drug abatacept to see if it can delay or prevent progression of early stage T1D (stage 1 or stage 2), and ultimately prevent clinical diagnosis (stage 3). In earlier studies for people newly diagnosed (stage 3), abatacept helped slow down disease progression. Details
If you are diagnosed with T1D while participating in one of our prevention studies, we’re still here for you. You can continue to receive personal monitoring while helping us learn more. More